1. Home
  2. CBRE vs INAB Comparison

CBRE vs INAB Comparison

Compare CBRE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBRE
  • INAB
  • Stock Information
  • Founded
  • CBRE 1906
  • INAB 2016
  • Country
  • CBRE United States
  • INAB United States
  • Employees
  • CBRE N/A
  • INAB N/A
  • Industry
  • CBRE Real Estate
  • INAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBRE Finance
  • INAB Health Care
  • Exchange
  • CBRE Nasdaq
  • INAB Nasdaq
  • Market Cap
  • CBRE 41.3B
  • INAB 14.5M
  • IPO Year
  • CBRE 2004
  • INAB 2021
  • Fundamental
  • Price
  • CBRE $143.18
  • INAB $2.27
  • Analyst Decision
  • CBRE Buy
  • INAB Strong Buy
  • Analyst Count
  • CBRE 9
  • INAB 2
  • Target Price
  • CBRE $152.11
  • INAB $108.00
  • AVG Volume (30 Days)
  • CBRE 1.4M
  • INAB 271.7K
  • Earning Date
  • CBRE 07-29-2025
  • INAB 08-07-2025
  • Dividend Yield
  • CBRE N/A
  • INAB N/A
  • EPS Growth
  • CBRE 2.39
  • INAB N/A
  • EPS
  • CBRE 3.28
  • INAB N/A
  • Revenue
  • CBRE $36,742,000,000.00
  • INAB N/A
  • Revenue This Year
  • CBRE $14.60
  • INAB N/A
  • Revenue Next Year
  • CBRE $9.27
  • INAB N/A
  • P/E Ratio
  • CBRE $43.72
  • INAB N/A
  • Revenue Growth
  • CBRE 13.15
  • INAB N/A
  • 52 Week Low
  • CBRE $86.19
  • INAB $2.05
  • 52 Week High
  • CBRE $147.75
  • INAB $27.30
  • Technical
  • Relative Strength Index (RSI)
  • CBRE 69.90
  • INAB 30.10
  • Support Level
  • CBRE $134.35
  • INAB $2.05
  • Resistance Level
  • CBRE $140.59
  • INAB $2.19
  • Average True Range (ATR)
  • CBRE 2.89
  • INAB 0.12
  • MACD
  • CBRE 0.61
  • INAB 0.06
  • Stochastic Oscillator
  • CBRE 88.77
  • INAB 37.61

About CBRE CBRE Group Inc

CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: